Sun Pharma Shares Fall Over 2% After US Pricing Pact; Tariff Relief Limits Losses
Add Preferred News Source
Sun Pharma shares fell over 2% in early trade after the company agreed to extend Most Favoured Nation (MFN) pricing to US state Medicaid programmes and future innovative medicine launches. The agreement also delays the application of Section 232 tariffs on its innovative pharmaceutical products for more than two years.
Sun Pharmaceutical Industries shares fell 2.3% in early trade on 01 September 2026 after the drugmaker agreed to lower US drug prices under an agreement with the US government.
The company will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes and future innovative medicine launches.
This fall has made the stock one of the top losers on the Nifty 50. The decline came after a 3.4% rise in the previous session and ended a three-session upward run during which the stock had risen around 4.5%.
At 11:52 AM, Sun Pharma shares were trading at ₹1,939.50, down 2.29% from the previous close on the National Stock Exchange (NSE). The stock touched a current intraday high of ₹1,963.10 in the early session.
Financial Impact Of The Agreement Remains Unclear
The remaining terms of the agreement are confidential. The pricing commitments could affect realisations from medicines covered by the arrangement.
Although the financial impact cannot yet be quantified because the company has not disclosed the products involved, applicable pricing benchmarks or the share of sales that could be affected.
The agreement was announced at a White House ceremony attended by several pharmaceutical companies. The companies were part of arrangements aimed at improving access to affordable medicines for American patients.
Section 232 Tariff Delay Provides Relief For Innovative Medicines
The agreement also includes a delay in the application of Section 232 tariffs on Sun Pharma's innovative pharmaceutical products for more than two years. The US government cited the company's investments in the country while providing the tariff concession.
The tariff delay is significant because the United States accounts for approximately 27% of Sun Pharma's global revenue. It is also the company's largest market for innovative medicines.
The company has been expanding beyond its traditional US generics business into innovative and speciality medicines. Its global innovative medicines portfolio, including dermatology, ophthalmology and onco-dermatology products, accounts for about 22% of company sales.
Sun Pharma's US Exposure Is Set To Increase
Sun Pharma’s exposure to the US market is also expected to rise after signing a definitive deal to acquire Organon & Co. The enterprise value of the transaction is $11.75 billion.
The movement in the Sun Pharma share price was there following the pricing deal, as the market is assessing the possible impact of reduced US medicine realisations versus the delay in Section 232 tariffs.
Also Read - PM Modi on 7.8% GDP growth: Why he wants Indians to avoid unnecessary gold buys and foreign trips
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights
